Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636371 | 0.84 | HPGD (0.43) | HPGDALDH1A1LMNAHTTKDM4E | |
| SCHEMBL502441 | 0.81 | ALDH1A1 (0.48) | HPGDSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL5487653 | 0.76 | NR1H4 (0.56) | MAPK14SMN1; SMN2RAB9AALDH1A1LMNA | |
| SCHEMBL14343804 | 0.74 | KDM4E (0.46) | HPGDMAPK14SMN1; SMN2RAB9ANPSR1 | |
| SCHEMBL12117445 | 0.74 | ALDH1A1 (0.49) | HPGDMAPK14ALDH1A1LMNAKDM4E | |
| SCHEMBL4809042 | 0.73 | MAPT (0.66) | MAPK14SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL8520317 | 0.73 | MPO (0.53) | ALDH1A1LMNAHTTKDM4EGAA | |
| SCHEMBL1628213 | 0.73 | ALDH1A1 (0.57) | MAPK14ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL15174212 | 0.73 | L3MBTL1 (0.43) | MAPK14L3MBTL1OGG1HDAC1 | |
| SCHEMBL2555304 | 0.72 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1LMNAKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2094698-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| WO-2008055842-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D] PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055842-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D] PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | MAP3K6, MAP3K1, MAP3K2 | HPGD 1299/4885MAPK14 44/4885SMN1; SMN2 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.